| Literature DB >> 32477409 |
J Abraham Avelar-Rivas1, Michelle Munguía-Figueroa1, Alejandro Juárez-Reyes1, Erika Garay1, Sergio E Campos1, Noam Shoresh2, Alexander DeLuna1.
Abstract
The chronological lifespan of budding yeast is a model of aging and age-related diseases. This paradigm has recently allowed genome-wide screening of genetic factors underlying post-mitotic viability in a simple unicellular system, which underscores its potential to provide a comprehensive view of the aging process. However, results from different large-scale studies show little overlap and typically lack quantitative resolution to derive interactions among different aging factors. We previously introduced a sensitive, parallelizable approach to measure the chronological-lifespan effects of gene deletions based on the competitive aging of fluorescence-labeled strains. Here, we present a thorough description of the method, including an improved multiple-regression model to estimate the association between death rates and fluorescent signals, which accounts for possible differences in growth rate and experimental batch effects. We illustrate the experimental procedure-from data acquisition to calculation of relative survivorship-for ten deletion strains with known lifespan phenotypes, which is achieved with high technical replicability. We apply our method to screen for gene-drug interactions in an array of yeast deletion strains, which reveals a functional link between protein glycosylation and lifespan extension by metformin. Competitive-aging screening coupled to multiple-regression modeling provides a powerful, straight-forward way to identify aging factors in yeast and their interactions with pharmacological interventions.Entities:
Keywords: Saccharomyces cerevisiae; gene-drug interactions; genetic analysis; high-throughput screening; post-mitotic aging
Year: 2020 PMID: 32477409 PMCID: PMC7240105 DOI: 10.3389/fgene.2020.00468
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
FIGURE 1Experimental and data-analysis workflow. (A) Starting cultures of fluorescence-tagged gene deletion (xΔ) and wild-type reference (WT) are grown separately. (B) Saturated cultures are mixed (usually in a 1:2 WT/xΔ ratio for increased dynamic range) and inoculated into SC aging medium in a semi-deep well plate until stationary phase (SP). (C) Competitive-aging cultures are sampled regularly at days t; outgrowth cultures in fresh medium are monitored at T hours with simultaneous measurement of absorbance at 600 nm (OD600), and raw RFP and CFP signals (Supplementary Figure S1). Possible differences in growth rate (G) are taken into account. (D) Data analysis uses the change in fluorescent-signal ratio in the outgrowth cultures to estimate the relative survivorship of each mutant (S). Data is fitted to a multiple linear-regression model considering the change of ln(RFP/CFP) empirical measurements over time as a function of the starting strains’ proportion (A), the mutant’s relative growth rate (G), systematic batch errors in the measurements (C), and the mutant’s survivorship relative to the wild-type (G), our parameter of interest (Supplementary Figure S2 and Note S1).
FIGURE 2The competitive-aging method is accurate and replicable. (A) Relative survivorship estimated by competitive aging. The modeled ln(RFP/CFP) is shown for the WT and ten mutant strains at each T point, averaged for at least six technical replicates along with the CI 95% (shaded area). (B) Percent of surviving cells in monoculture over time measured by the shift in outgrowth kinetics; the mean and CI 95% are shown. (C) Average relative survivorship of three to five experimental replicates is shown, expressed either as the difference of individual death rates for monoculture outgrowth kinetics (r−r, black) or as survivorship coefficients for competitive aging (S, red). Each data point is the average of at least six technical replicates of monocultures or competitions in an independent experimental replicate. Horizontal lines are the mean of each data series. Stacked bars below the plot indicate the number of replicate plates per sample; solid fraction indicates the number of significant samples compared with the WT distribution (p < 0.01, t-test; each experimental batch has 31 reference and at least six deletion samples).
FIGURE 3Identification of gene-drug interactions by competitive-aging screening. (A) Half life of WT-reference samples with (n = 39) or without metformin (n = 40). (B) Scatter plot comparing the CLS phenotypes of 76 gene-deletion strains with or without metformin; the average rescaled relative survivorship rS shown of four replicates is shown. Color scale indicates the p-value of paired t-tests between the S in SC and SC + Metformin. (C) Gene-drug interactions confirmed by live/dead staining. Survival curves of wild-type (light colors) and gene-deletion (dark colors) strains in nominal SC medium (green) or SC + metformin (orange); 95% CI were calculated from at least three replicates (shaded area). The interaction between metformin and gene-deletions was scored significant by two-way ANOVA tests of the death rates (***p < 0.01).